Business description: Scholar Rock Holding Corporation

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.

Number of employees: 289

Sales by Activity: Scholar Rock Holding Corporation

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Pharmaceuticals

18.82M 33.19M - - -

Geographical breakdown of sales: Scholar Rock Holding Corporation

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States

18.82M 33.19M - - -

Executive Committee: Scholar Rock Holding Corporation

Manager TitleAgeSince
Chief Executive Officer 59 27/04/2025
Director of Finance/CFO 62 27/04/2025
Chief Operating Officer 58 27/04/2025
Chief Tech/Sci/R&D Officer 48 29/01/2025
Chief Tech/Sci/R&D Officer 51 01/09/2022

Composition of the Board of Directors: Scholar Rock Holding Corporation

Director TitleAgeSince
Chairman 59 01/07/2017
Director/Board Member 53 01/08/2014
Director/Board Member 78 01/10/2016
Director/Board Member 70 01/11/2013
Director/Board Member 63 21/05/2019
Director/Board Member 53 18/03/2021
Director/Board Member 58 26/07/2022
Director/Board Member 68 06/04/2023
Director/Board Member 55 15/02/2024

Shareholders: Scholar Rock Holding Corporation

NameStocks%Valuation
Fidelity Management & Research Co. LLC
15.66 %
17,995,241 15.66 % 851 M $
The Invus Group LLC
8.335 %
9,575,013 8.335 % 453 M $
The Invus Group LLC
8.335 %
9,575,013 8.335 % 453 M $
BlackRock Advisors LLC
7.779 %
8,936,378 7.779 % 423 M $
Samsara BioCapital LLC
6.004 %
6,897,652 6.004 % 326 M $

Company details: Scholar Rock Holding Corporation

Scholar Rock Holding Corp.

301 Binney Street

02142, Cambridge

+857 259 3860

http://www.scholarrock.com
address Scholar Rock Holding Corporation(SRRK)

Bio Therapeutic Drugs

Change 5-day change 1-year change 3-year change Capi.($)
-1.30%+7.26%+71.92%+874.67% 7.31B
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+2.51%+49.34%+93.39% 65.4B
-1.03%+0.46%+8.14%-5.28% 28.28B
-2.41%-2.95%-9.77%+455.82% 27.16B
+0.69%-0.49%+63.50%+12.15% 26.57B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.37%+1.21%+36.55%-15.78% 20.09B
-2.00%-4.28%+13.44%+531.90% 15.87B
-1.50%+2.92%+43.50%+151.30% 13.9B
Average -0.18%+1.95%+60.71%+262.22% 29.56B
Weighted average by Cap. +0.65%+1.09%+56.86%+173.37%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
59.26USD
Average target price
60.75USD
Spread / Average Target
+2.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock
  4. Company Scholar Rock Holding Corporation